Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb657 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | XmAb657 administered SC |
| Name | Type | Description |
|---|---|---|
| XmAb657 | BIOLOGICAL | Biological |
Inclusion Criteria: Healthy participants - Adult participants in good health Idiopathic inflammatory myopathy (IIM) participants - Adult participants that meet the 2017 European Alliance of Association Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criterion for IIM Sy...
XmAb657 is an investigational monoclonal antibody developed by Xencor, Inc. for idiopathic inflammatory myopathies, a group of autoimmune muscle disorders. It is in Phase 1 clinical development and has not been approved by any regulatory agency. Xencor is studying it in immunology, with a single active trial currently recruiting participants.
XmAb657 targets CD19, a protein found on the surface of B cells. By binding CD19, the antibody is designed to engage B cells, the immune cell class implicated in antibody-driven autoimmune conditions such as idiopathic inflammatory myopathies. CD19-directed approaches aim to reduce the B-cell contribution to autoimmune disease activity.
Xencor, Inc. is developing XmAb657. Xencor is a clinical-stage biopharmaceutical company traded on the Nasdaq under the ticker XNCR. The company discovered and is running the Phase 1 program for XmAb657 in idiopathic inflammatory myopathies and related autoimmune conditions.
XmAb657 is in Phase 1 clinical development. It is investigational and has not been approved for any indication. The Phase 1 program is an open-label study evaluating safety in healthy participants and participants with autoimmune diseases, and it is currently recruiting.
XmAb657 is being studied in one active clinical trial, NCT07284797, titled a Phase 1 open-label study to evaluate safety in healthy participants and participants with autoimmune diseases. The trial is recruiting, plans to enroll 60 participants, and is being conducted in Australia in adults 18 years and older.
XmAb657 is being developed as a potential treatment for idiopathic inflammatory myopathies, a group of autoimmune conditions affecting muscle. It is investigational and not approved for this or any other use. The Phase 1 trial also enrolls participants with systemic sclerosis and Sjogren's disease alongside healthy volunteers.